Sun Pharma saw a sharp rise in ANDA approvals though, from 37 in FY19 to 45 in FY20. The company has invested $2 bn in its specialty portfolio in the US. It has also guided that research and development (R&D) costs would rise to 8-9 per cent of sales over a period of time. In the fourth quarter of the fiscal, it was 6.1 per cent of sales.
Analysts feel that Indian companies
have not only decided to focus on high margin, low competition products, but many plants were also under the the FDA scanner in the last one year or so. This resulted in a slight slowdown in the rate of approvals for some players. We have created our launch pipeline and the last two years saw a slew of filings and approvals. The lower run rate in FY20 is because of that. And going forward we would be selective in our approach when it comes to filing for products, said a senior official of a leading US focussed company.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.